Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed melanoma~  * Stage III (≥ 3 positive lymph nodes) or stage IV disease~ * Mucosal or ocular melanoma allowed~* Completely resected within the past 6 months~* Patients with stage III resected melanoma rendered free of disease may have failed, been ineligible for, or refused prior treatment with interferon alfa~* Positive staining of tumor tissue for at least one of the following:~  * Antibody HMB-45 for gp100~ * Antibody HMB-45 for tyrosinase~ * Antibody HMB-45 for MART-1~* HLA-A\*0201 positive by DNA allele-specific polymerase chain reaction assay~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* At least 6 months~Hematopoietic~* WBC ≥ 2,500/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hematocrit ≥ 30%~* Hemoglobin ≥ 10 g/dL~Hepatic~* AST ≤ 3 times upper limit of normal (ULN)\*~* Bilirubin ≤ ULN\* (\< 3.0 mg/dL for patients with Gilbert's syndrome)~* No significant hepatic disease that would preclude study participation~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative NOTE: \* Unless attributable to disease~Renal~* Creatinine ≤ 2.0 mg/dL~* No significant renal disease that would preclude study participation~Cardiovascular~* No significant cardiac disease that would preclude study participation~Pulmonary~* No significant pulmonary disease that would preclude study participation~Immunologic~* No history of any of the following:~  * Inflammatory bowel disease or any other autoimmune bowel disease~ * Systemic lupus erythematosus~ * Rheumatoid arthritis~ * Autoimmune ocular disease~* No systemic hypersensitivity to Montanide ISA-51 or any vaccine component~* No active infection requiring therapy~* HIV negative~Other~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix~* No significant gastrointestinal disease that would preclude study participation~* No significant psychiatric disease that would preclude study participation~* No other medical condition that would preclude study participation~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 4 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010)~* No prior gp100 antigen, MART-1 antigen, or tyrosinase peptide~* At least 4 weeks since prior immunotherapy for melanoma and recovered~* No other concurrent immunotherapy~Chemotherapy~* At least 4 weeks since prior chemotherapy for melanoma (6 weeks for nitrosoureas) and recovered~* No concurrent chemotherapy~Endocrine therapy~* At least 4 weeks since prior hormonal therapy for melanoma and recovered~* At least 4 weeks since prior systemic, inhaled, or topical corticosteroids~* No concurrent systemic, inhaled, or topical corticosteroids~Radiotherapy~* At least 4 weeks since prior radiotherapy for melanoma and recovered~Surgery~* See Disease Characteristics~* At least 4 weeks since prior surgery for melanoma and recovered~Other~* No concurrent immunosuppressive agents (e.g., cyclosporine and its analog)~* Concurrent analgesic therapy allowed provided the dose is stable for the past 14 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).